|
|
Latest Rectal Cancer News
Rectal Cancer Increasing in People Under 40 (9/2/2010)
Although still relatively uncommon in young people, the incidence of rectal cancer appears to be increasing in this population. These results were published in the journal Cancer.
Pathological Complete Response Predicts Better Outcomes in Locally Advanced Rectal Cancer Patients (8/25/2010)
Among patients with locally advanced rectal cancer, a complete disappearance of detectable cancer (pathological complete response) after preoperative chemoradiation therapy is linked with better long-term outcomes. These findings were recently published in the journal The Lancet Oncology.
Antibiotic Sponge Ineffective at Preventing Surgical Infection (8/12/2010)
Patients undergoing colorectal surgery are reported to experience an increased incidence of surgical-site infection with the addition of a gentamicin-collagen sponge enclosed at the surgery site. These findings were recently published in the New England Journal of Medicine.
Radioembolization plus Fluorouracil Active in Colorectal Cancer Patients with Liver Metastases (7/2/2010)
Radioembolization plus the chemotherapy agent fluorouracil slows cancer progression for colorectal cancer patients whose disease has progressed following prior treatment with chemotherapy and have metastases limited to the liver.
Depression May Persist With Metastatic Cancer (5/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.
Rectal Cancer News By Topic
Rectal Cancer - Screening/PreventionRectal Cancer Increasing in People Under 40 (9/2/2010)
Although still relatively uncommon in young people, the incidence of rectal cancer appears to be increasing in this population. These results were published in the journal Cancer.
Rates of Adenoma Detection Linked to Risk of Interval Colorectal Cancer (5/18/2010)
Endoscopists who detect tumors or polyps (adenomas) at a higher rate during colonoscopy screening for colorectal cancer tend to produce a lower risk for interval cancer among their patients, according to a study published in the New England Journal of Medicine.
Colorectal Cancer Screening with Flexible Sigmoidoscopy Reduces Incidence and Death (5/6/2010)
Among individuals between 55 and 64 years of age, one screening using flexible sigmoidoscopy can reduce risk of developing colorectal cancer and dying from the disease, according to a study published in The Lancet.
Lower Use of Diagnostic Testing May Explain Higher Colorectal Cancer Mortality in African Americans (4/6/2010)
The higher incidence and mortality from colorectal cancer among African Americans compared with Whites may be due to differences in health care utilization rather than differences in susceptibility to cancer, according to a study published in the Journal of the National Cancer Institute.
Low Levels of Vitamin B6 May Increase Risk of Colorectal Cancer (3/23/2010)
Individuals with low blood levels of an active form of vitamin B6 or low dietary intake of vitamin B6 may have an increased risk of developing colorectal cancer. These results, based on an analysis of several previously published studies, were published in the Journal of the American Medical Association.
Rectal Cancer - Stages I-IIIPathological Complete Response Predicts Better Outcomes in Locally Advanced Rectal Cancer Patients (8/25/2010)
Among patients with locally advanced rectal cancer, a complete disappearance of detectable cancer (pathological complete response) after preoperative chemoradiation therapy is linked with better long-term outcomes. These findings were recently published in the journal The Lancet Oncology.
Antibiotic Sponge Ineffective at Preventing Surgical Infection (8/12/2010)
Patients undergoing colorectal surgery are reported to experience an increased incidence of surgical-site infection with the addition of a gentamicin-collagen sponge enclosed at the surgery site. These findings were recently published in the New England Journal of Medicine.
Most Survivors of Lung and Colorectal Cancer Keep Their Jobs (4/14/2010)
Among people diagnosed with nonmetastatic lung or colorectal cancer, the majority return to work, according to a study recently published in Journal of Clinical Oncology. Those who do leave the workforce tend to have worse prognoses and lower socioeconomic status.
Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.
Physical Activity Improves Survival of Men with Localized Colorectal Cancer (12/23/2009)
Men who report the most physical activity after a diagnosis of non-metastatic colorectal cancer have a lower risk of death than men who report the least activity. These results were published in the Archives of Internal Medicine.
Rectal Cancer - Stage IVRadioembolization plus Fluorouracil Active in Colorectal Cancer Patients with Liver Metastases (7/2/2010)
Radioembolization plus the chemotherapy agent fluorouracil slows cancer progression for colorectal cancer patients whose disease has progressed following prior treatment with chemotherapy and have metastases limited to the liver.
Depression May Persist With Metastatic Cancer (5/27/2010)
A substantial number of patients with metastatic cancer may suffer from depression which tends to persist and grow more severe toward the end of life, according to the results of a study published early online in the Journal of Clinical Oncology.
Study Explores Which Patients Respond Best to Vectibix (4/19/2010)
Previous studies have reported that colorectal cancers with mutations in a gene known as KRAS do not respond well to drugs such as Vectibix® (panitumumab). In an effort to expand these findings and further individualize colorectal cancer treatment, researchers evaluated several additional genes. The results were presented at the 101st annual meeting of the American Association for Cancer Research.
Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.
Preventive Treatment Reduces Skin Side Effects of Vectibix (2/16/2010)
Among patients with metastatic colorectal cancer treated with the targeted therapy Vectibix® (panitumumab), preventive skin care reduces the occurrence of skin side effects. These results were published in the Journal of Clinical Oncology.
Rectal Cancer - Recurrent/RelapsedRadioembolization plus Fluorouracil Active in Colorectal Cancer Patients with Liver Metastases (7/2/2010)
Radioembolization plus the chemotherapy agent fluorouracil slows cancer progression for colorectal cancer patients whose disease has progressed following prior treatment with chemotherapy and have metastases limited to the liver.
Sandostatin Ineffective in Preventing Diarrhea in Anal and Rectal Cancer Patients Treated with Chemoradiotherapy (3/30/2010)
Sandostatin® (ocreotide acetate) does not prevent diarrhea in patients with anal or rectal cancer treated with chemotherapy and radiation therapy. The results of this randomized, double-blind, placebo controlled trial were recently reported in the Journal of the National Cancer Institute.
Preventive Treatment Reduces Skin Side Effects of Vectibix (2/16/2010)
Among patients with metastatic colorectal cancer treated with the targeted therapy Vectibix® (panitumumab), preventive skin care reduces the occurrence of skin side effects. These results were published in the Journal of Clinical Oncology.
Vectibix Improves Outcome of Previously Treated Colorectal Cancer (1/27/2010)
Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain a mutation in the KRAS gene. These results were presented at the 2010 ASCO Gastrointestinal Cancers Symposium.
March Is National Colorectal Cancer Awareness Month (3/3/2009)
As the month of March brings colon cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated colorectal cancer information throughout the year.
|
